About: The road to new antiviral therapies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The road to new antiviral therapies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The road to new antiviral therapies
Creator	Jerome, Keith
source	Elsevier; Medline; PMC
abstract	Viral diseases continue to pose some of the greatest challenges to modern medicine. For many viral diseases, prophylactic vaccines are unlikely to be developed in the near future. Fortunately, effective antiviral therapies have been developed for many of these viruses. In this review, I will focus on antiviral therapy for herpes simplex virus, human immunodeficiency virus, hepatitis C virus, and human papillomavirus. The development of compounds targeting these viruses illustrates many of the principles driving current antiviral development. It is likely that our increasing understanding of viral replication and the virus-host interaction will lead to more rapid development of new antivirals in the future.
has issue date	2005-01-22(xsd:dateTime)
bibo:doi	10.1016/j.cair.2004.10.002
bibo:pmid	32362789
has license	no-cc
sha1sum (hex)	6a252fc8863c36bf9f697948912eb53359d8ca93
schema:url	https://doi.org/10.1016/j.cair.2004.10.002
resource representing a document's title	The road to new antiviral therapies
has PubMed Central identifier	PMC7185762
has PubMed identifier	32362789
schema:publication	Clin Appl Immunol Rev
resource representing a document's body	covid:6a252fc8863c36bf9f697948912eb53359d8ca93#body_text
is schema:about of	named entity 'effective' named entity 'human immunodeficiency virus' named entity 'targeting' named entity 'HUMAN PAPILLOMAVIRUS' named entity 'MODERN MEDICINE' named entity 'VIRUS-HOST INTERACTION' named entity 'LEAD' named entity 'DRIVING' named entity 'CONTINUE' named entity 'HERPES SIMPLEX VIRUS' named entity 'CURRENT' named entity 'HEPATITIS C VIRUS' named entity 'RAPID' named entity 'UNLIKELY' named entity 'DEVELOPMENT' named entity 'ANTIVIRAL THERAPY' named entity 'REVIEW' named entity 'FUTURE' named entity 'NEAR' named entity 'OUR' named entity 'TARGETING' named entity 'ANTIVIRAL' named entity 'LIKELY' named entity 'EFFECTIVE' named entity 'HUMAN IMMUNODEFICIENCY VIRUS' named entity 'INCREASING' named entity 'PROPHYLACTIC' named entity 'VIRAL REPLICATION' named entity 'UNDERSTANDING' named entity 'NEW' named entity 'THERAPIES' named entity 'ANTIVIRAL' named entity 'ANTIVIRALS' named entity 'NEW' named entity 'GREATEST' named entity 'HAVE' named entity 'VIRUSES' named entity 'POSE' named entity 'VACCINES' named entity 'THESE' named entity 'FOCUS' named entity 'CHALLENGES' named entity 'ROAD' named entity 'THERAPIES' named entity 'VIRAL DISEASES' named entity 'lead' named entity 'development' named entity 'antiviral' named entity 'hepatitis C virus' named entity 'antivirals' named entity 'herpes simplex virus' named entity 'antiviral' named entity 'viral diseases' named entity 'Viral diseases' named entity 'modern medicine' named entity 'viral replication' named entity 'antiviral therapies' named entity 'future' named entity 'developed' named entity 'ribavirin' named entity 'pharmaceutical companies' named entity 'cutaneous' named entity 'HIV' named entity 'viral replication' named entity 'lesion' named entity 'HIV' named entity 'nucleoside analogs' named entity 'HIV' named entity 'herpes simplex virus' named entity 'protease inhibitor' named entity 'interferon-α' named entity 'antibacterial compounds' named entity 'chronic infection' named entity 'immune modulation' named entity 'Vidarabine' named entity 'SARS coronavirus' named entity 'nucleoside' named entity 'protease inhibitors' named entity 'AZT' named entity 'polymerase' named entity 'bacterial infections'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software